Insider Cluster (2 insiders) ·Filed Feb 23, 2026

IRWD

IRONWOOD PHARMACEUTICALS INC
BEARISH
Impact 7/10
Horizondays Processed7mo ago
Insider cluster: 2 insiders, $401K total
Actionable Insight ▼ Bearish

Traders should monitor for upcoming earnings, potential downgrades, or corporate developments that may have prompted coordinated executive selling. Absent strong positive news, this level of selling by C-suite executives often precedes negative catalysts or reflects diminished confidence in near-term prospects.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
IRWD ▼ -6.67% at T+60d
SHORT call ✓ call won +6.67% · α vs SPY +14.92% · entry $3.75 → $3.50
Entry anchored
Feb 20, 03:59 PM ET
via exchange tick
T+1d
+1.07%
call -1.07% · α -0.33%
$3.79
settled 7mo ago
T+5d
-4.80%
call +4.80% · α +5.42%
$3.57
settled 7mo ago
T+20d
-12.27%
call +12.27% · α +8.32%
$3.29
settled 7mo ago
T+60d
-6.67%
call +6.67% · α +14.92%
$3.50
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Ironwood Pharmaceuticals CEO Thomas McCourt and CFO Gregory Martini collectively sold over $821,000 worth of shares in open-market transactions over two days, with both executives selling significant blocks at prices between $3.66 and $3.81 per share. This represents a coordinated insider selling event involving the company's top two executives.

Key Financial Metrics

Direction
selling
Total Value
$821.8K
Insiders
2

Key Facts

  • CEO Thomas McCourt sold 198,283 shares for $739,929.33 in two transactions on Feb 23–24, 2026
  • CFO Gregory Martini sold 21,944 shares for $81,888.09 in two transactions on same dates
  • Total insider selling cluster: 220,227 shares, $821,817.42 total value
  • All transactions were open-market sales (Form 4 code 'S') — not forced or tax-related
  • Sales occurred at declining prices: $3.81 down to $3.66, suggesting possible urgency or lack of price sensitivity

Financial Impact

$821,817 in net insider selling over 7 days

insider ownershipinvestor sentimentpotential dilution risk if proceeds used for corporate purposes

Risk Factors

  • Insider selling can signal lack of confidence in future stock performance
  • Concentrated selling by both CEO and CFO increases negative perception risk
  • Potential for downward price pressure if market interprets this as bearish signal

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (4 trades, 7d window)cluster-IRWD-1772053905883
6 reports for IRWD
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+20▲ +12.27%Feb 23, 2026
Filters
Rows
Reports for IRWD — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
8-K
BULLISH ★ 7/10
$4.26 $4.29▲ +0.70%▲ +0.10%$3.62 (−15.02%)
May 13, 2026
20w ago
8-K
MIXED ★ 6/10
$3.68 $3.63▼ −1.36%▼ −0.75%$3.62 (−1.63%)
May 7, 2026
21w ago
8-K
BULLISH ★ 7/10
$4.17 $3.24▼ −22.30%▼ −25.44%$3.62 (−13.19%)
Feb 25, 2026
31w ago
8-K
BEARISH ★ 5/10
$3.36 $3.19▲ +5.06%▼ −0.18%$3.62 (−7.74%)
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 6/10
$3.75 $3.29▲ +12.27%▲ +8.32%$3.62 (+3.47%)
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 7/10
$3.75 $3.29▲ +12.27%▲ +8.32%$3.62 (+3.47%)
Showing 6 of 6

US Market Status

Market Open — Closes in 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Feb 25, 2026